NeuroSense Therapeutics – Study of New Drug to Treat ALS
Alon Ben-Noon, CEO and co-founder of NeuroSense Therapeutics, a clinical-stage biotechnology company focused on treatments for neurodegenerative disease
3313 articles
Alon Ben-Noon, CEO and co-founder of NeuroSense Therapeutics, a clinical-stage biotechnology company focused on treatments for neurodegenerative disease
Lisa Jones-Engel, Senior Science Advisor on primate experimentation with People for the Ethical Treatment of Animals (PETA) discusses her prior work wit...
Melissa Rogne, Founder and President of Chapter Aesthetic Studio discusses their expansion over the next two years with a unique focus on communities wh...
In the coming months, the FDA is expected to finalize its proposed rule to make certain hearing aids available over the counter, which will allow consum...
Eleni Efstathiou, MD, PhD, Section Chief of Genitourinary Medical Oncology at Houston Methodist Oncology Partners and an investigator on the Phase...
Mitzi Joi Williams, board-certified neurologist, fellowship-trained multiple sclerosis specialist and Founder and CEO of the Joi Life Wellness Group Mul...
Robyn Knecht, Director of Counseling Services at the Saint Joseph's Indian School in South Dakota discusses the school; equine therapy and the benefits ...
Steve Sell, CEO of agilon health, the trusted partner empowering physicians to transform community health, and Andy Mueller, MD, CEO of MaineHealth, the...
Richard Johnson, MD, Gout Education Society board member and a professor of medicine at the University of Colorado discusses his new book "Nature Want...
Dave Rosa, President and CEO discusses NeuroOne, a medical technology company focused on the development and commercialization of minimally invasive and...